Shuttle Pharmaceuticals Announces \$3.5 Million Public Offering: Key Details for Investors

Summary of the Announcement

Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a developer of AI-driven platforms for molecular discovery and early-stage drug development, has entered into a securities purchase agreement to raise approximately \$3.5 million in a public offering. This financing round is a critical development for the company and is expected to close on or about March 9, 2026, subject to customary closing conditions.

Key Points of the Offering

• Aggregate Gross Proceeds: The company aims to raise approximately \$3.5 million before deducting placement agent fees and other offering expenses.
• Securities Issued: The offering consists of 2,238,800 shares of common stock and pre-funded warrants to purchase an additional 4,761,200 shares of common stock.
• Placement Agent: E.F. Hutton & Co. is acting as the exclusive placement agent for the transaction.
• Use of Proceeds: Up to \$1.5 million of the net proceeds will be allocated for future marketing efforts, while the remainder will be used for working capital and general corporate purposes.
• Offering Details: The securities are being offered under a registration statement on Form S-1 (File No. 333-293363), which became effective on February 17, 2026.

Why This Matters for Shareholders

• Potential Share Price Impact: The issuance of new shares and pre-funded warrants will increase the number of outstanding shares, potentially diluting existing shareholders. However, the infusion of capital strengthens the company’s balance sheet and enables further investment in product development and marketing.
• Growth Strategy: The targeted use of proceeds for marketing and general corporate purposes signals an aggressive push towards market expansion and operational stability. This may improve the company’s competitive position in the AI-driven pharmaceutical discovery industry.
• Regulatory Compliance: The offering is being conducted in accordance with SEC regulations, and all terms are publicly filed, ensuring transparency for investors.

About Shuttle Pharmaceuticals Holdings, Inc.

Shuttle Pharmaceuticals owns and operates Molecule.ai, an artificial intelligence-driven software platform designed to enhance molecular discovery and accelerate early-stage drug development. The platform integrates advanced AI techniques with structured scientific workflows, enabling researchers to explore chemical space more efficiently, evaluate molecular concepts with greater clarity, and make better-informed decisions in the initial phases of drug development.

Forward-Looking Statements and Risks

Investors should note that the press release contains forward-looking statements regarding the completion of the offering, future plans, and the company’s prospects. These statements are subject to various risks, including the company’s ability to satisfy closing conditions, general economic and market risks, and other factors discussed in the company’s filings with the SEC. Actual results may differ materially from those projected in forward-looking statements.

Important Information for Investors

• The offering is expected to close on or about March 9, 2026, but is subject to customary closing conditions.
• Details of the offering are available through the SEC and E.F. Hutton & Co. upon request.
• Shareholders should consider the potential dilutive effect of the new shares and warrants, as well as the intended use of proceeds to support corporate growth and marketing initiatives.

Disclaimer

This article is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities. Investors should carefully review official filings and consult their financial advisor before making investment decisions. Forward-looking statements are subject to risks and uncertainties; Shuttle Pharmaceuticals Holdings, Inc. undertakes no obligation to update forward-looking statements unless required by law.

View Shuttle Pharmaceuticals Holdings, Inc. Historical chart here